CV Sciences (CVSI) EPS (Basic) (2011 - 2026)

CV Sciences (CVSI) posted EPS (Basic) of -$0.0 for Q1 2026, down 493.7% sequentially from $0.0 in Q4 2025, and down 481.53% YoY from $0.0 in Q1 2025.

CV Sciences (CVSI) EPS (Basic) (2011 - 2026) Analysis & Trends

CV Sciences has reported EPS (Basic) for 16 years, with the latest figure at -$0.0 in Q1 2026.

Quarterly EPS (Basic) fell 481.53% year-over-year to -$0.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.01 (up 31.29% YoY) and the FY2025 annual result came in at -$0.0, up 76.48% from the prior year.
EPS (Basic) retreated to -$0.0 in Q1 2026 per CVSI's latest filing, from $0.0 in the prior quarter.
Over five years, EPS (Basic) peaked at $0.04 in Q1 2023 and troughed at -$0.03 in Q2 2022.
A 5-year average of -$0.0 and a median of -$0.0 in 2024 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2023: EPS (Basic) plunged 1819.36% in 2022, then surged 307.23% in 2023.
Over 5 years, EPS (Basic) stood at -$0.02 in 2022, then surged by 66.31% to -$0.01 in 2023, then jumped by 53.08% to -$0.0 in 2024, then soared by 132.99% to $0.0 in 2025, then tumbled by 493.7% to -$0.0 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.0, $0.0, and -$0.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Haleon	43.76 Bn	42.79 Bn	-	-
2	Teva Pharmaceutical Industries	43.38 Bn	39.73 Bn	2.15 Bn	-0.49
3	Zoetis	31.61 Bn	29.93 Bn	1.05 Bn	2.07
4	Takeda Pharmaceutical	28.64 Bn	22.84 Bn	5.10 Bn	0.45
5	United Therapeutics	22.20 Bn	19.54 Bn	683.80 Mn	7.82
6	Viatris	18.82 Bn	17.93 Bn	1.46 Bn	-0.10
7	Neurocrine Biosciences	15.67 Bn	15.28 Bn	935.80 Mn	1.43
8	Elanco Animal Health	12.11 Bn	11.58 Bn	798.00 Mn	0.11
9	Dr Reddys Laboratories	10.10 Bn	9.94 Bn	-	-
10	CV Sciences	4.12 Mn	3.86 Mn	1.45 Mn	0.00

Download Data